Extended biopsy protocol decreases prostate cancer incidence and risk of aggressive disease on repeated biopsies compared with initial standard procedure.
OBJECTIVE
To compare prostate cancer detection rates in repeated biopsy depending on the number of cores at initial biopsy.


METHODS
Out of 3,000 consecutive patients, 534 underwent repeat extended biopsies. At first procedure, 345 patients had undergone standard biopsies (10-15 cores; SBx) whereas 189 other patients had already had a 21-core extended protocol (ExtBx). Clinicobiological and pathological parameters were compared between 2 groups.


RESULTS
The prostate cancer detection rate was significantly higher in the SBx group (37%) compared with the ExtBx group (16.8%, p < 0.001). Mean PSA level, mean percent free PSA and mean prostate volume were equivalent in both groups. Thirty-eight percent of cancers detected in the SBx group were graded Gleason 7 or more, compared with 19.3% in the ExtBx group (p = 0.018). Mean percent of core invasion was 25.3% in the SBx group compared to 15.9% in the ExtBx group (p = 0.004).


CONCLUSIONS
A full evaluation of all prostate zones using ExtBx seems to be necessary to decrease the risk of undetected prostate cancer on repeated biopsies. For patients who had at their first biopsy an ExtBx, the risk of prostate cancer on the repeated biopsies and the risk of aggressive cancer were lower compared to standard biopsies.
Ploussard
Guillaume
G
INSERM U588 Eq07 Departments of Urology and Pathology, APHP, CHU Henri Mondor, Créteil, France.
Bastien
Laurence
L
Descazeaud
Aurélien
A
Robert
Grégoire
G
Allory
Yves
Y
Salomon
Laurent
L
Vordos
Dimitri
D
Hoznek
Andreas
A
Yiou
René
R
Abbou
Claude-Clément
CC
de la Taille
Alexandre
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D049109:Cell Proliferation; D006801:Humans; D015994:Incidence; D008297:Male; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging / Q000379:methods; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000453:epidemiology*; D012306:Risk
D017430:Prostate-Specific Antigen